A novel recombinant fusion protein which delivers the p21 protein to the cell nucleus and, in combination with conventional chemotherapy, achieves tumor eradication and increases survival in animals.
- ANTP-p21 fusion protein delivers the p21 protein to the cell nucleus. Immunofluorescence studies shown below demonstrate that nuclear delivery of the tumor suppressor protein is achieved in ovarian carcinoma cells.
- Biodistribution of ANTP-p21 in tumor-bearing animals
In vivo experiments have shown that the ANTP-p21 fusion protein readily distributes to all tissues as expected and will thus be available to suitably vascularised tumours.
- Animal Models
- Little evidence of toxicity and immunogenicity
- Good evidence of activity in xenografts
- Synergy with chemotherapy
- Statistically significant increase in the survival of tumor-bearing animals
- Patient Studies
ANTP-p21 is currently being formulated in order to be used in a Phase I clinical study.